MNMD — Mind Medicine (MindMed) Share Price
0.000.00%
Last trade - 00:00- $434.88m
- $182.99m
- 37
- 25
- 50
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.8 | ||
| Price to Tang. Book | 1.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.5% | ||
| Return on Equity | -68.01% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Directors
- Carol Vallone CHM (64)
- Miriam Wernli PRE
- Robert Barrow CEO
- Andreas Krebs VCH
- David Guebert CFO
- Carol Nast COO
- Bradford Cross CTO
- Donald Gehlert CSO
- Daniel Karlin OTH
- Sarah Vinson DRC
- Brigid Makes IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 26th, 2010
- Public Since
- May 4th, 2015
- No. of Shareholders
- 78
- No. of Employees
- 74
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 75,368,359
- Address
- One World Trade Center, Suite 8500, NEW YORK, 10007
- Web
- Phone
- +1 2122206633
- Auditors
- KPMG LLP
Upcoming Events for MNMD
Mind Medicine (MindMed) Inc Annual Shareholders Meeting
Q2 2025 Mind Medicine (MindMed) Inc Earnings Release
Similar to MNMD
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Mind Medicine (MindMed) share price?
As of Today at 22:03 UTC, shares in Mind Medicine (MindMed) are trading at $5.77. This share price information is delayed by 15 minutes.
How has the Mind Medicine (MindMed) share price performed this year?
Shares in Mind Medicine (MindMed) last closed at $5.77 and the price had moved by -39.45% over the past 365 days. In terms of relative price strength the Mind Medicine (MindMed) share price has underperformed the S&P500 Index by -43.07% over the past year.
What are the analyst and broker recommendations for Mind Medicine (MindMed)?
The overall consensus recommendation for Mind Medicine (MindMed) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Mind Medicine (MindMed) dividend yield?
Mind Medicine (MindMed) does not currently pay a dividend.
Does Mind Medicine (MindMed) pay a dividend?
Mind Medicine (MindMed) does not currently pay a dividend.
When does Mind Medicine (MindMed) next pay dividends?
Mind Medicine (MindMed) does not currently pay a dividend.
How do I buy Mind Medicine (MindMed) shares?
To buy shares in Mind Medicine (MindMed) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mind Medicine (MindMed)?
As of the previous close price of $5.77, shares in Mind Medicine (MindMed) had a market capitalisation of $434.88m.
Where are Mind Medicine (MindMed) shares listed?
Here are the trading details for Mind Medicine (MindMed):
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MNMD
What kind of share is Mind Medicine (MindMed)?
Based on an overall assessment of its quality, value and momentum Mind Medicine (MindMed) is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mind Medicine (MindMed) share price forecast for 2025?
The analyst consensus target price for shares in Mind Medicine (MindMed) is $24.67. That is 327.56% above the last closing price of $5.77.
Analysts covering Mind Medicine (MindMed) currently have a consensus Earnings Per Share (EPS) forecast of -$1.57 for the next financial year.
Find out moreWhat is the trend in the Mind Medicine (MindMed) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mind Medicine (MindMed). Over the past six months, its share price has underperformed the S&P500 Index by -3.27%.
As of the last closing price of $5.77, shares in Mind Medicine (MindMed) were trading -16.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mind Medicine (MindMed) PE Ratio?
The Mind Medicine (MindMed) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mind Medicine (MindMed)?
Mind Medicine (MindMed)'s management team is headed by:
- Carol Vallone - CHM
- Miriam Wernli - PRE
- Robert Barrow - CEO
- Andreas Krebs - VCH
- David Guebert - CFO
- Carol Nast - COO
- Bradford Cross - CTO
- Donald Gehlert - CSO
- Daniel Karlin - OTH
- Sarah Vinson - DRC
- Brigid Makes - IND